NCT05130866Phase 2, phase 3Terminated

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

Study sponsor: Recursion Pharmaceuticals Inc. · RXRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-08-18Actual
Enrollment · participants25Actual
Source updated2026-08-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview